drugset / Trial / NCT02769169

Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy

NCT02769169

Phase 2/3 Terminated 5 enrolled Sun Yat-sen University
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether double-dose Ranibizumab are effective to regress the polyps and benefit to the visual outcome in the polypoidal choroidal vasculopathy (PCV).

Timeline

Start
2018-08-01
Primary completion
2018-09-12
Completion
2018-12-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ranibizumab Monoclonal antibody 0.5 mg Intravitreal
Comparator Ranibizumab Monoclonal antibody 1 mg Intravitreal